We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+62.1%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.18B
AUM Growth
+$1.19B
Cap. Flow
+$143M
Cap. Flow %
3.41%
Top 10 Hldgs %
48.69%
Holding
88
New
15
Increased
28
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$127M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$72.2M
3
BSX icon
Boston Scientific
BSX
+$68.3M
4
APRE icon
Aprea Therapeutics
APRE
+$62.5M
5
UNH icon
UnitedHealth
UNH
+$52.9M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$155M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$114M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$87.2M
4
CELG
Celgene Corp
CELG
+$55.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$49.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Industrials 0.33%
3 Technology 0%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
51
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$17.6M 0.42%
1,136,806
-2,300
-0.2% -$27.8K
STXS icon
52
Stereotaxis
STXS
$145M
$16.8M 0.4%
3,169,308
-115,692
-4% -$460K
GTHX
53
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$16.2M 0.39%
613,734
+222,800
+57% +$5.21M
CYRX icon
54
CryoPort
CYRX
$815M
$13.9M 0.33%
+842,363
New +$12.5M
ADPT icon
55
Adaptive Biotechnologies
ADPT
$4.02B
$12.7M 0.3%
425,700
+1,700
+0.4% +$48.8K
VAPO
56
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$11.7M 0.28%
119,942
– –
CBIO
57
Crescent Biopharma
CBIO
$659M
$7.11M 0.17%
13,438
-6,538
-33% -$3.54M
BNTX icon
58
BioNTech
BNTX
$25.6B
$5.88M 0.14%
+173,500
New +$3.89M
CBAY
59
DELISTED
Cymabay Therapeutics
CBAY
$5.51M 0.13%
2,813,565
-302,300
-10% -$1.14M
GOSS icon
60
Gossamer Bio
GOSS
$83.2M
$4.07M 0.1%
260,300
-200
-0.1% -$4.03K
SYRS
61
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.47M 0.04%
21,229
-367,646
-95% -$22.3M
OVID icon
62
Ovid Therapeutics
OVID
$547M
$506K 0.01%
121,950
– –
ELGX
63
DELISTED
Endologix Inc
ELGX
$124K ﹤0.01%
78,755
– –
CSLT
64
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$14K ﹤0.01%
10,229
– –
ANAB icon
65
AnaptysBio
ANAB
$1.67B
– –
-612,558
Closed -$21.4M
BCRX icon
66
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-75,000
Closed -$215K
DXCM icon
67
DexCom
DXCM
$34.3B
– –
-1,216,632
Closed -$45.4M
ESTA icon
68
Establishment Labs
ESTA
$2.11B
– –
-10,000
Closed -$189K
INSP icon
69
Inspire Medical Systems
INSP
$1.78B
– –
-3,910
Closed -$239K
JAZZ icon
70
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-187,599
Closed -$24M
LIVN icon
71
LivaNova
LIVN
$4.43B
– –
-342,987
Closed -$25.3M
NBIX icon
72
Neurocrine Biosciences
NBIX
$15.7B
– –
-2,740
Closed -$247K
PEN icon
73
Penumbra
PEN
$12.7B
– –
-297,972
Closed -$40.1M
VCEL icon
74
Vericel Corp
VCEL
$2.1B
– –
-16,720
Closed -$253K
VKTX icon
75
Viking Therapeutics
VKTX
$3.75B
– –
-16,260
Closed -$112K
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2019 Portfolio in Review

As of Q4 2019, Redmile Group held 88 positions worth $4.18B, up 40% from $2.99B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group deployed $143M of net new capital in Q4 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Biogen: 457,500 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Audentes Therapeutics, Inc, an estimated $87.2M trimmed.

  • Redmile Group's largest Q4 2019 buy was Biogen: 457,500 shares worth $136M.
  • Redmile Group added most to Principia Biopharma Inc. Common Stock in Q4 2019, an estimated $72.2M increase.
  • Redmile Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $87.2M.
  • Redmile Group fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $155M.
  • Redmile Group's ten largest holdings make up 49% of its $4.18B portfolio in Q4 2019.
  • Redmile Group opened 15 new positions and closed 24 in Q4 2019.
  • Redmile Group's portfolio value rose 40% quarter-over-quarter to $4.18B.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.